Treatment selection after imatinib resistance in chronic myeloid leukemia

Targeted Oncology

Volumn 4, Issue 1, 2009, Pages 3-10

  Jabbour, Elias ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Imatinib; Second line therapy

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOGENETICS; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LIVER TOXICITY; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG UTILIZATION; FUSION PROTEINS, BCR-ABL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; STEM CELL TRANSPLANTATION; THIAZOLES; TREATMENT FAILURE;

EID: 67349179696     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0100-y     Document Type: Review

References (77)

1. National Comprehensive Cancer Network (2008) Chronic myelogenous leukemia V.I.2008. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/ professionals/physician-gls/PDF/cml.pdf . Accessed 19 Sept 2008
2. European LeukemiaNet (2008) Management of chronic myeloid leukemia (CML): recommendations from the European LeukemiaNet (ELN). http://www.leukemia-net. org/content/leukemias/cml/standards-sops/recommendations/ . Accessed 2 Sept 2008
3. JD Griffin RF Todd III J Ritz LM Nadler GP Canellos D Rosenthal 1983 Differentiation patterns in the blastic phase of chronic myeloid leukemia Blood 61 1 85 91 (Pubitemid 13169770)
4. P Bettelheim D Lutz O Majdic E Paietta O Haas W Linkesch 1985 Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia Br J Haematol 59 3 395 409 (Pubitemid 15132940)
5. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340 (Pubitemid 29196596)
6. HM Kantarjian M Talpaz 1988 Definition of the accelerated phase of chronic myelogenous leukemia J Clin Oncol 6 1 180 182 (Pubitemid 18071248)
7. PC Nowell DA Hungerford 1960 A minute chromosome in human chronic granulocytic leukemia Science 132 1497
8. JD Rowley 1973 A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290-293
9. TG Lugo AM Pendergast AJ Muller ON Witte 1990 Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1079-1082 (Pubitemid 20102464)
10. AM Pendergast LA Quilliam LD Cripe CH Bassing Z Dai N Li 1993 BCRABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein Cell 75 175 185 (Pubitemid 23306031)
11. L Puil J Liu G Gish G Mbamalu D Bowtell PG Pelicci 1994 Bcr-Abi oncoproteins bind directly to activators of the Ras signalling pathway EMBO J 13 764 773 (Pubitemid 24057507)
12. R Marais Y Light HF Paterson CJ Marshall 1995 Ras remits Raf-I to the plasma membrane for activation by tyrosine phosphorylation EMBO J 14 3136 3145
13. T Skorski P Kanakaraj M Nieborowska-Skorska MZ Ratajczak SC Wen G Zon 1995 Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood 86 726 736
14. T Skorski A Bellacosa M Nieborowska-Skorska M Majewski R Martinez JK Choi 1997 Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway EMBO J 16 6151 6161 (Pubitemid 27458335)
15. TF Franke DR Kaplan LC Cantley 1997 PBK: downstream AKTion blocks apoptosis Cell 88 435 437 (Pubitemid 27154408)
16. K Shuai J Halpern J ten Hoeve X Rao CL Sawyers 1996 Constitutive activation of STAT5 by the Bcr-Abl oncogene in chronic myelogenous leukemia Oncogene 13 247 254 (Pubitemid 26334856)
17. RL Haria Jr RA Van Etten 1996 P2IO and PI90(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members J Biol Chem 271 31704 31710 (Pubitemid 26408636)
18. A Klejman SJ Schreiner M Nieborowska-Skorska A Slupianek M Wilson TE Smithgall 2002 The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells EMBO J 21 5766 5774 (Pubitemid 35315274)
19. A Menssen H Hermeking 2002 Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes Proc Natl Acad Sci USA 99 6274 6279 (Pubitemid 34493302)
20. CL Sawyers W Callahan ON Witte 1992 Dominant negative MYC blocks transformation by ABL oncogenes Cell 70 901 910
21. DE Alar A Goga J McLaughlin ON Witte CL Sawyers 1994 Differential complementation of Bcr-Abl point mutants with c-Myc Science 264 424 426 (Pubitemid 24178905)
22. T Skorski M Nieborowska-Skorska P Wlodarski D Perrotti R Martinez MA Wasik 1996 Blastic transformation of p53-deficient bone marrow cells by p2lObcr/abl tyrosine kinase Proc Natl Acad Sci USA 93 13137 13142 (Pubitemid 26382782)
23. M Serrano H Lee L Chin C Cordon-Cardo D Beach RA DePinho 1996 Role of the INK4a locus in tumor suppression and cell mortality Cell 85 2737 (Pubitemid 26116804)
24. Z Beck A Kiss FD Tóth J Szabó A Bácsi E Balogh 2000 Alterations ofP53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia Leuk Lymphoma 38 587 597 (Pubitemid 30614544)
25. C Sherr F McCormick 2002 The RB and p53 pathways in cancer Cancer Cell 2 2 103 112 (Pubitemid 41039110)
26. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994-1004 (Pubitemid 36302244)
27. Novartis Pharmaceuticals Corporation (2007) Imatinib prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec-tabs.pdf Accessed 16 Oct 2008
28. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. (2009) Chronic Myelogenous Leukemia http://www.nccn.org/professionals/ physician-gls/PDF/cml.pdf . Accessed 15 Oct 2008
29. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408-2417
30. MY Hamdan L Sanders S Oliveria U Campbell V Willey I Hirji 2007 Discontinuation and dose modification of imatinib in clinical practice J Clin Oncol 25 18S 7045
31. CL Sawyers A Hochhaus E Feldman JM Goldman CB Miller OG Ottmann 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530 3539 (Pubitemid 34534519)
32. M Talpaz RT Silver BJ Druker JM Goldman C Gambacorti-Passerini F Guilhot 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928 1937 (Pubitemid 34525471)
33. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 652
34. HM Kantarjian M Talpaz S O'Brien F Giles G Garcia-Manero S Faderl 2003 Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Blood 101 2 473 475 (Pubitemid 36077567)
35. JA Zonder P Pemberton H Brandt AN Mohamed CA Schiffer 2003 The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment Clin Cancer Res 9 6 2092 2097 (Pubitemid 36687630)
36. HM Kantarjian A Hochhaus J Cortes G Martinelli KN Bhalla FJ Giles 2007 Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia patients with imatinib-resistance or intolerance Blood 110 226a
37. D Marin JM Goldman E Olavarria JF Apperley 2003 Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses Blood 102 7 2702 2703 (Pubitemid 37193621)
38. E Jabbour H Kantarjian E Atallah G Borthakur W Wierda S Faderl 2007 Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) Blood 110 1035 (Pubitemid 46425867)
39. A Hochhaus S Kreil AS Corbin P La Rosée MC Müller T Lahaye 2002 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2190 2196 (Pubitemid 35331833)
40. NJ Donato JY Wu J Stapley G Gallick H Lin R Arlinghaus 2003 BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 690 698 (Pubitemid 36077594)
41. DL White VA Saunders P Dang J Engler AC Zannettino AC Cambareri 2006 OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2 697 704 (Pubitemid 44061372)
42. J Goldman M Gordon 2006 Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47 1 1 7 (Pubitemid 43101717)
43. J Cortes F Giles S O'Brien 2003 Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha Blood 102 1 83 86 (Pubitemid 36759639)
44. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 (Pubitemid 32267972)
45. HM Kantarjian M Talpaz S O'Brien G Garcia-Manero S Verstovsek F Giles 2004 High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2873 2878 (Pubitemid 38451654)
46. Y Hu Y Liu S Pelletier E Buchdunger M Warmuth D Fabbro 2004 Requirement of Src kinases Lyn, Hck and Fgr for Bcr-Abll-induced B-Iymphoblastic leukemia but not chronic myeloid leukemia Nat Genet 36 5 453 461 (Pubitemid 38620028)
47. A Ptasznik Y Nakata A Kalota SG Emerson AM Gewirtz 2004 Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABLI(+) leukemia cells Nat Med 10 11 1187 1189 (Pubitemid 39540433)
48. J Cortes P Rousselot DW Kim E Ritchie N Hamerschlak S Coutre 2007 Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood 109 3207-3213 (Pubitemid 46572505)
49. F Guilhot J Apperley DW Kim EO Bullorsky M Baccarani GJ Roboz 2007 Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood 109 4143-4150 (Pubitemid 46743375)
50. A Hochhaus HM Kantarjian M Baccarani JH Lipton JF Apperley BJ Druker 2007 Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2303-2309 (Pubitemid 46425867)
51. H Kantarjian R Pasquini N Hamerschlak P Rousselot J Holowiecki S Jootar 2007 Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of frontline imatinib: a randomized phase 2 trial Blood 109 5143 5150 (Pubitemid 46890528)
52. O Ottmann H Dombret G Martinelli B Simonsson F Guilhot RA Larson 2007 Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 110 2309-2315 (Pubitemid 47523149)
53. MJ Mauro M Baccarani F Cervantes JH Lipton Y Matloub R Sinha 2008 Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) J Clin Oncol 26 suppl 7009a
54. Shah NP, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Gerard B et al (2006) Dasatinib (D) vs high dose imatinib (lM) in patients with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. Proc Am Soc Clin Oncol 24:abstract 6507
55. Martinelli G, Rousselot P, Robak T, Masszi T, Skotnicki A, Hellmann A et al (2007) Comparison of dasatinib to high-dose imatinib in patients who experience imatinib failure: results from a randomized, phase-II trial (CA180017, START-R). Haematologica 92:abstract 0862
56. Bristol-Myers Squibb Company (2007) Dasatinib prescribing information. http://packageinserts.bms.com/pi/pi-sprycel.pdf . Accessed 16 Oct 2008
57. M Talpaz NP Shah H Kantarjian N Donato J Nicoll R Paquette 2006 Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias N Engl J Med 354 2531 2541 (Pubitemid 43882349)
58. FR Luo Z Yang A Camuso R Smykla K McGlinchey K Fager 2006 Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure Clin Cancer Res 12 7180 7186
59. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, et al (2008) Intermittent target inhibition with dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol In press
60. HM Kantarjian F Giles N Gatterman 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540 3546 (Pubitemid 350159618)
61. HM Kantarjian FJ Giles A Hochhaus KN Bhalla GJ Ossenkoppele N Gattermann 2008 Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results J Clin Oncol 26 15S 7010
62. FJ Giles RA Larson HM Kantarjian P le Coutre M Baccarani A Haque 2007 Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis who are resistant or intolerant to imatinib Blood 110 310a
63. P le Coutre OG Ottmann F Giles DW Kim J Cortes N Gattermann 2008 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Blood 111 1834 1839
64. Novartis Pharmaceuticals Corporation. (2007) Nilotinib prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Accessed 16 Oct 2008
65. C Gambacorti-Passerini H Kantarjian T Bruemmendorf G Martinelli M Baccarani T Fischer 2007 Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL Blood 110 146a
66. JM Golas K Arndt C Etienne J Lucas D Nardin J Gibbons 2003 SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res 63 375 381 (Pubitemid 36152495)
67. S Kimura H Naito H Segawa J Kuroda T Yuasa K Sato 2005 NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 3948 3954 (Pubitemid 41739036)
68. HM Kantarjian J Cortes P le Coutre A Nagler J Pinilla A Hochhaus 2007 A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors Blood 110 144a (Pubitemid 350159618)
69. AR Craig HM Kantarjian JE Cortes D Jones A Hochhaus S O'Brien 2007 A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib J Clin Oncol 25 18S 7046
70. HM Kantarjian S O'Brien J Cortes FJ Giles S Faderl JP Issa 2003 Results of decitabine (5'-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 522 528 (Pubitemid 36885992)
71. JP Issa V Gharibyan J Cortes J Jelinek G Morris S Verstovsek 2005 Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 23 3948 3956 (Pubitemid 46218698)
72. A Benichou HJ Khoury S Corm FE Nicolini AR Craig E Humphriss 2008 Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation J Clin Oncol 26 15S 7021
73. Y Oki HM Kantarjian V Gharibyan D Jones S O'Brien S Verstovsek 2007 Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 109 899 906 (Pubitemid 46333532)
74. E Jabbour J Cortes HM Kantarjian S Giralt D Jones R Jones 2006 Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure Blood 108 4 1421 1423 (Pubitemid 44232047)
75. E Jabbour H Kantarjian D Jones M Breeden G Garcia-Manero S O'Brien 2008 Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood 112 53 55
76. S Soverini S Colarossi A Gnani G Rosti F Castagnetti A Poerio 2006 Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 7374 7379 (Pubitemid 46095411)
77. T Hughes G Saglio G Martinelli DW Kim S Soverini M Mueller 2007 Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types Blood 110 11 320